Objective To provide estimates of maternal age-and gestational age-related risks for trisomy 21. 
INTRODUCTION
Estimates of the maternal age-related risk for trisomy 21 at birth are based on two surveys with almost complete ascertainment; in a survey in South Belgium, every neonate was examined for features of trisomy 21, and, in a survey in Sweden, information was verified using several sources such as hospital notes, cytogenetic laboratories, genetic clinics and schools for the mentally handicapped [1] [2] [3] . During the past decade, with the introduction of maternal serum biochemistry and ultrasound screening for chromosomal defects at different stages of pregnancy, it has become necessary to establish maternal age-and gestational age-specific risks for chromosomal defects. Previous studies derived such estimates by comparing the birth prevalence of trisomy 21 1 to the prevalence reported in two multicenter studies on amniocentesis at 16-20 weeks of gestation 4, 5 and the prevalence in small series on chorionic villus sampling at 9-14 weeks of gestation 6, 7 . In this study, we revised our previous estimates by examining 57 614 pregnancies that were karyotyped at 9-16 weeks of gestation. Furthermore, we examined the accuracy of these estimates in a group of 96 127 singleton pregnancies with complete follow-up that were recruited at 10-14 weeks of gestation 8 .
SUBJECTS AND METHODS

Estimate of risk
To calculate estimates of risk for trisomy 21 at different gestations, we used data from 57 614 women who had fetal karyotyping at 9-16 weeks of gestation for the sole indication of maternal age of 35 years or more. On the basis of the maternal age distribution and maternal age-related risk for trisomy 21 at birth 1 number of trisomy 21 cases was calculated for each gestational age subgroup (9-10 weeks, 11-14 weeks and 15-16 weeks) and for each maternal age. In these calculations, the appropriate corrections were made for those women whose age in years would increase between the time of antenatal assessment at 9-16 weeks and the time of delivery. Gestational age was available in completed weeks. Pearson correlation analysis was applied to examine whether the ratio changed significantly with maternal age and/or gestation. Regression analysis was applied to ratios at 9-10 weeks, 11-14 weeks, 15-16 weeks and 40 weeks (where the ratio was set at one) to derive a smoothened curve for the decrease in ratio with gestational age.
Validation of the model
In a multicenter study of screening for trisomy 21 by combination of maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation, we obtained details on the outcome of 96 127 pregnancies 8 . This group included 326 pregnancies with trisomy 21. The new formula for maternal age-and gestational age-related risk was applied to this population, to calculate the expected number of trisomy 21 pregnancies, and this number was compared to the observed number of 326.
RESULTS
The maternal age and gestational age distributions of the 57 614 pregnancies are shown in Table 1 . Trisomy 21 was diagnosed in 538 cases ( Table 2 ). The relative prevalence of trisomy 21 (observed to expected ratio), compared to a prevalence of 1.0 at 40 weeks, was not significantly associated with maternal age (r = 0.178; p = 0.31) but decreased with gestational age (r = 0.812; p < 0.01). Data were grouped to derive the relative prevalence at different gestations (Table 3 ) and regression analysis was applied to derive a smoothened curve Table 3 Observed number of cases with trisomy 21 compared to the number expected in live births in relation to gestational age
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[log10(relative prevalence) = 0.2718 × log10(gestation) 2 − 1.023 × log10(gestation) + 0.9425]. The estimated maternal age-and gestational age-related risks for trisomy 21 are given in Table 4 . The estimated rates of spontaneous fetal death between different gestations and delivery at 40 weeks were derived on the basis of the relative prevalences between these gestations and 40 weeks ( Table 5) .
Validation of the model
The accuracy of the model was examined on the basis of findings in 96 127 pregnancies examined at 10-14 weeks of gestation. The expected number of cases with trisomy 21 was estimated to be 329 (95% confidence interval 291-361). This number is not significantly different from the observed number of 326 cases (χ 2 = 0.02). There was no significant difference between the observed and expected numbers for different gestational age and maternal age subgroups (Table 6) .
DISCUSSION
This study provides revised estimates of maternal age-and gestational age-related risk for trisomy 21. Compared to our previous report 7 , in this study the number of cases with fetal karyotyping was much higher (57 614 compared to 15 793). Additionally, in this study the appropriate corrections were made for the increase in maternal age with advancing gestation.
The estimates for the rate of spontaneous fetal death for trisomy 21 are lower than in our previous report (30% compared to 41% for the loss rate between 12 and 40 weeks of gestation and 21% compared to 31% for the loss rate between 16 and 40 weeks) 7 . The main reason for this apparent discrepancy is that in the previous analysis there was no correction for the increase in maternal age with advancing gestation. This led to an underestimate for the expected number of trisomy 21 live births and thus to an overestimate of the loss rate. The new estimates of loss rates are similar to the 31% from 12 weeks and 18% from 16 weeks reported by Halliday and colleagues 9 ; they compared the prevalence of trisomy 21 in 10 545 women having chorionic villus sampling or amniocentesis for the sole indication of maternal age of 36 years or more, to the prevalence in live births from 12 921 women of similar age who did not have fetal karyotyping 9 . Assessment of the model on the basis of findings in 96 127 pregnancies indicates that the estimated prevalences are accurate at least for the gestational range of 10-14 weeks; the estimates at 16 weeks and 20 weeks of gestation require validation with an independent data set.
The model makes it possible to counsel patients presenting at different stages of pregnancy concerning the risk that their fetus has trisomy 21 and the chances that the pregnancy will result in a live birth with this condition. Furthermore, the data can be used to calculate the expected 
